Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?

BJU International

Volumn 90, Issue 6, 2002, Pages 579-585

  Adsan, O ^a   Cecchini, M G ^a   Bisoffi, M ^a   Wetterwald, A ^a   Klima, I ^a   Danuser, H J ^a   Studer, U E ^a   Thalmann, G N ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biochemical recurrence; Prostate cancer; PSA; PSMA; RT PCR

Indexed keywords

BIOCHEMICAL MARKER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOLLOW UP; GENE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SOUTHERN BLOTTING; TREATMENT OUTCOME; TUMOR CELL;

BLOTTING, SOUTHERN; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0036378325     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02972.x     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 2000; 50: 7-33
2. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93
3. Israeli RS, Miller WH Jr, Su SL et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54: 6306-10
4. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-35
5. Sokoloff MH, Tso CL, Kaboo R et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging. a clinicopathological molecular analysis of 121 patients. J Urol 1996; 156: 1560-6
6. Seiden MV, Kantoff PW, Krithivas K et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634-9
7. Ellis WJ, Vessella RL, Corey E et al. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998; 159: 1134-8
8. Katz AE, de Vries GM, Begg MD et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75: 1642-8
9. De la Taille A, Olsson CA, Buttyan R et al. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen. long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 1999; 84: 360-4
10. Okegawa T, Nutahara K, Higashihara E. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. BJU Int 1999; 84: 112-7
11. Baier G, Telford D, Gulbins E, Yamada N, Kawakami T, Altman A. Improved specificity of RT-PCR amplifications using nested cDNA primers. Nucl Acids Res 1993; 21: 1329-30
12. Myers TW, Gelfand DH. Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase. Biochemistry 1991; 30: 7661-6
13. Partin AW, Kattan MW, Subong NP et al. Combination of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-51
14. Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18
15. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51: 3753-61
16. Israeli RS, Miller WH Jr, Su SL et al. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 1995; 153: 573-7
17. Nejat RJ, Katz AE, Olsson CA. The role of reverse transcriptase-polymerase chain reaction for staging patients with clinically localized prostate cancer. Sem Oncol 1998; 16: 40-5
18. Gao CL, Maheshwari S, Dean RC et al. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology 1999; 53: 714-21
19. Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications. Eur Urol 1998; 36: 278-84
20. Thiounn N, Saporta F, Flam TA et al. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 1997; 50: 245-50
21. Zhang Y, Zippe CD, Van Lente F, Klein EA, Gupta MK. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 1997; 3: 1215-20
22. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998; 58: 1456-9
23. Melchior SW, Corey E, Ellis WJ et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3: 249-56
24. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24
25. Oefelein MG, Kaul K, Herz B et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol 1996; 155: 238-42
26. Eschwege P, Dumas F, Blanchet P et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995; 346: 1528-30
27. Ghossein RA, Scher HI, Gerald WL et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Onc 1995; 13: 1195-200
28. Berteau P, Dumas F, Gala JL et al. Influence of blood storage and sample processing on molecular detection of circulating prostate cancer cells in cancer. Clin Chem 1998; 44: 677-9
29. Henke W, Jung M, Jung K et al. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 1997; 70: 52-6
30. Ghossein RA, Osman I, Bhattacharya S et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagnostic Mol Pathol 1999; 8: 59-65
31. Theodorescu D, Frierson HF Jr, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 1999; 161: 1442
32. Kraeft S-K, Sutherland R, Gravelin L et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 2000; 6: 434-42
33. Straub B, Müller M, Krause H et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using the 'Light-Cycler'-based quantitative real-time polymerase chain reaction. Urology 2001; 58: 815-20
34. Ylikoski A, Karp M, Pettersson K, Lilja H, Lovgren T. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients. J Mol Diagn 2001; 3: 111-22